Welcome to GRIN !

 

What is GRIN?  

genetics-group-1

Inspired by a common vision of accelerated genomic discovery, collaboration, and improved clinical outcomes, leaders at Boston Children’s Hospital (BCH), Cincinnati Children’s Hospital Medical Center (CCHMC) and the Children’s Hospital of Philadelphia (CHOP) have come together to propose the creation of the Genomics Research and Innovation Network (GRIN).

What are GRIN’s goals?

Research into genetic causes of disease is limited by the ability to rapidly recruit sufficient numbers of patients at any one institution. A national interconnected, multi-institutional infrastructure can bring together the power of numbers to accelerate research into the genetic causes of disease.  This work would include significant effort in establishing multi-institutional agreements through  legal, privacy, regulatory, academic and technical infrastructure working groups.

By synergizing the collective academic and clinical assets at each institution, GRIN will help scientists make novel molecular discoveries, accelerate the translation of genomic findings to clinical care, and establish a culture of collaborative genomic medicine across pediatrics. The combination of genetic and health information from the three leading pediatric institutions into a usable, scalable infrastructure creates an unparalleled capability. This unique resource will form the foundation for landmark insights into the genetic basis of pediatric and adult disease, as well as accelerating the advent of precision medicine for child health.

Five key outcomes of GRIN are expected:

  • Providing a common, shared community of practice for collaborative genomic studies
  • Creating a broad knowledge base of annotated genomic and clinical data for variant interpretation
  • Establishing a “big data” environment to benefit discovery, translational science, and trainee development
  • Facilitating cohort expansion – especially valuable in the study of rare disease
  • Enhancing team science by matching disparate disease and analysis experts around genomic challenges